Gilead Sciences (NASDAQ:GILD) Updates FY 2020 After-Hours Earnings Guidance

Gilead Sciences (NASDAQ:GILD) issued an update on its FY 2020
After-Hours earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.25-7.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.71. The company issued revenue guidance of $23-25 billion, compared to the consensus revenue estimate of $23.44 billion.Gilead Sciences also updated its FY20 guidance to $6.25-7.65 EPS.

Shares of GILD stock opened at $69.53 on Friday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04. Gilead Sciences has a fifty-two week low of $60.89 and a fifty-two week high of $85.97. The stock has a 50 day moving average price of $75.47 and a two-hundred day moving average price of $73.57. The company has a market capitalization of $87.22 billion, a P/E ratio of -289.70, a PEG ratio of 2.34 and a beta of 0.70.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.46). Gilead Sciences had a positive return on equity of 32.17% and a negative net margin of 1.16%. The firm had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.24 billion. As a group, equities analysts predict that Gilead Sciences will post 6.79 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a dividend yield of 3.91%. Gilead Sciences’s dividend payout ratio (DPR) is 44.30%.

A number of research analysts recently issued reports on GILD shares. Needham & Company LLC restated a hold rating on shares of Gilead Sciences in a report on Tuesday, June 30th. JPMorgan Chase & Co. restated a hold rating and set a $85.00 target price on shares of Gilead Sciences in a report on Tuesday, July 28th. Oppenheimer reiterated a buy rating on shares of Gilead Sciences in a report on Monday, May 18th. Maxim Group restated a hold rating on shares of Gilead Sciences in a report on Tuesday, June 2nd. Finally, Cantor Fitzgerald reaffirmed a buy rating and issued a $86.00 target price on shares of Gilead Sciences in a research report on Friday. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $79.63.

In other news, EVP Brett A. Pletcher sold 13,210 shares of the business’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $79.23, for a total value of $1,046,628.30. Following the completion of the transaction, the executive vice president now owns 27,204 shares in the company, valued at $2,155,372.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Diane E. Wilfong sold 12,264 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $80.09, for a total value of $982,223.76. Following the sale, the chief accounting officer now directly owns 23,685 shares in the company, valued at $1,896,931.65. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,079 shares of company stock worth $2,240,630. Insiders own 0.13% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Cost of Equity For A Business, Investors

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.